Kuros Biosciences AG (CSBTF)
USD 22.57
(0.0%)
USD 22.57
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 19.19 Million CHF | 36.26% |
| 2022 | 14.08 Million CHF | -1.91% |
| 2021 | 14.36 Million CHF | 47.09% |
| 2020 | 9.76 Million CHF | -2.34% |
| 2019 | 9.99 Million CHF | 7.06% |
| 2018 | 9.33 Million CHF | -27.84% |
| 2017 | 12.94 Million CHF | 137.62% |
| 2016 | 5.44 Million CHF | 110.27% |
| 2015 | 2.59 Million CHF | -94.09% |
| 2014 | 43.85 Million CHF | 20.89% |
| 2013 | 36.27 Million CHF | 78.14% |
| 2012 | 20.36 Million CHF | -52.08% |
| 2011 | 42.49 Million CHF | -10.5% |
| 2010 | 47.47 Million CHF | -21.48% |
| 2009 | 60.46 Million CHF | -23.37% |
| 2008 | 78.89 Million CHF | 14.13% |
| 2007 | 69.12 Million CHF | 500.46% |
| 2006 | 11.51 Million CHF | 37.33% |
| 2005 | 8.38 Million CHF | 2.34% |
| 2004 | 8.19 Million CHF | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 17.12 Million CHF | 0.0% |
| 2024 Q1 | 17.12 Million CHF | -10.76% |
| 2023 Q1 | 14.29 Million CHF | 1.49% |
| 2023 Q2 | 14.29 Million CHF | -0.01% |
| 2023 FY | 19.19 Million CHF | 36.26% |
| 2023 Q3 | 14.75 Million CHF | 3.2% |
| 2023 Q4 | 19.19 Million CHF | 30.11% |
| 2022 Q4 | 14.08 Million CHF | 0.0% |
| 2022 FY | 14.08 Million CHF | -1.91% |
| 2022 Q1 | 15.06 Million CHF | 4.92% |
| 2022 Q2 | 15.06 Million CHF | 0.0% |
| 2022 Q3 | 14.08 Million CHF | -6.5% |
| 2021 Q2 | 8.53 Million CHF | 0.0% |
| 2021 FY | 14.36 Million CHF | 47.09% |
| 2021 Q3 | 14.36 Million CHF | 68.23% |
| 2021 Q4 | 14.36 Million CHF | 0.0% |
| 2021 Q1 | 8.53 Million CHF | -12.57% |
| 2020 Q1 | 8.72 Million CHF | -12.72% |
| 2020 Q4 | 9.76 Million CHF | 0.0% |
| 2020 Q3 | 9.76 Million CHF | 11.9% |
| 2020 FY | 9.76 Million CHF | -2.34% |
| 2020 Q2 | 8.72 Million CHF | 0.0% |
| 2019 Q3 | 9.99 Million CHF | 0.52% |
| 2019 Q1 | 9.94 Million CHF | 6.5% |
| 2019 FY | 9.99 Million CHF | 7.06% |
| 2019 Q4 | 9.99 Million CHF | 0.0% |
| 2019 Q2 | 9.94 Million CHF | 0.0% |
| 2018 FY | 9.33 Million CHF | -27.84% |
| 2018 Q4 | 9.33 Million CHF | 131.14% |
| 2018 Q3 | 4.04 Million CHF | -60.65% |
| 2018 Q2 | 10.26 Million CHF | 247.01% |
| 2018 Q1 | 2.95 Million CHF | -77.13% |
| 2017 Q3 | 4.65 Million CHF | -64.85% |
| 2017 Q2 | 13.24 Million CHF | 172.01% |
| 2017 Q1 | 4.87 Million CHF | -10.58% |
| 2017 FY | 12.94 Million CHF | 137.62% |
| 2017 Q4 | 12.94 Million CHF | 177.94% |
| 2016 Q4 | 5.44 Million CHF | 66.8% |
| 2016 Q2 | 5.71 Million CHF | 148.13% |
| 2016 FY | 5.44 Million CHF | 110.27% |
| 2016 Q1 | 2.3 Million CHF | -11.04% |
| 2016 Q3 | 3.26 Million CHF | -42.89% |
| 2015 Q2 | 1.56 Million CHF | 0.0% |
| 2015 Q4 | 2.59 Million CHF | -49.64% |
| 2015 FY | 2.59 Million CHF | -94.09% |
| 2015 Q3 | 5.14 Million CHF | 229.05% |
| 2014 FY | 43.85 Million CHF | 20.89% |
| 2014 Q4 | 43.85 Million CHF | 0.0% |
| 2014 Q2 | 37.55 Million CHF | 0.0% |
| 2013 Q4 | 36.27 Million CHF | 33.68% |
| 2013 Q3 | 27.13 Million CHF | 18.76% |
| 2013 Q2 | 22.84 Million CHF | 9.83% |
| 2013 FY | 36.27 Million CHF | 78.14% |
| 2013 Q1 | 20.8 Million CHF | 2.16% |
| 2012 Q4 | 20.36 Million CHF | -7.31% |
| 2012 FY | 20.36 Million CHF | -52.08% |
| 2012 Q3 | 21.96 Million CHF | 18.43% |
| 2012 Q2 | 18.55 Million CHF | 12.32% |
| 2012 Q1 | 16.51 Million CHF | -61.13% |
| 2011 Q4 | 42.49 Million CHF | -11.14% |
| 2011 Q1 | 47.14 Million CHF | -0.7% |
| 2011 Q2 | 46.31 Million CHF | -1.75% |
| 2011 FY | 42.49 Million CHF | -10.5% |
| 2011 Q3 | 47.82 Million CHF | 3.25% |
| 2010 Q3 | 46.62 Million CHF | 2.72% |
| 2010 Q1 | 52.4 Million CHF | -13.32% |
| 2010 FY | 47.47 Million CHF | -21.48% |
| 2010 Q4 | 47.47 Million CHF | 1.82% |
| 2010 Q2 | 45.39 Million CHF | -13.39% |
| 2009 FY | 60.46 Million CHF | -23.37% |
| 2009 Q4 | 60.46 Million CHF | 0.0% |
| 2008 FY | 78.89 Million CHF | 14.13% |
| 2007 FY | 69.12 Million CHF | 500.46% |
| 2006 FY | 11.51 Million CHF | 37.33% |
| 2005 FY | 8.38 Million CHF | 2.34% |
| 2004 FY | 8.19 Million CHF | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 63.992% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -100.313% |
| SQZ Biotechnologies Company | 50.03 Million USD | 61.642% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 73.515% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 67.476% |
| Mesoblast Limited | 188.44 Million USD | 89.815% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -398.361% |
| Genus plc | 485 Million USD | 96.042% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -228.517% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -662.778% |
| Marizyme, Inc. | 26.67 Million USD | 28.047% |
| ContraFect Corporation | 32.53 Million USD | 40.998% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -405.105% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -868.754% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -401.457% |
| Intellipharmaceutics International Inc. | 12 Million USD | -59.833% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -62.962% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1186421.355% |
| Accustem Sciences Inc. | 1.07 Million USD | -1678.475% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 75.207% |
| EV Biologics, Inc. | 2.11 Million USD | -807.488% |
| Q BioMed Inc. | 8.13 Million USD | -136.003% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 76.857% |
| Neon Bloom, Inc. | 1.22 Million USD | -1465.307% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -272.986% |
| Biomind Labs Inc. | 1.49 Million USD | -1180.785% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 92.136% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -4.296% |
| Skye Bioscience, Inc. | 14.07 Million USD | -36.396% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -854.864% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -13407.864% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -102.769% |
| IMV Inc. | 37.93 Million USD | 49.4% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -9443.746% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -234.051% |
| GB Sciences, Inc. | 5.41 Million USD | -254.293% |
| Alpha Cognition Inc. | 7.16 Million USD | -167.894% |
| HST Global, Inc. | 593.59 Thousand USD | -3133.529% |
| CSL Limited | 18.62 Billion USD | 99.897% |
| Halberd Corporation | 728.71 Thousand USD | -2533.937% |
| Enzolytics Inc. | 365.26 Million USD | 94.745% |
| Resverlogix Corp. | 67.39 Million USD | 71.521% |
| Affymax, Inc. | 8.87 Million USD | -116.368% |
| SYBLEU INC | 681.41 Thousand USD | -2716.794% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -2188.454% |
| argenx SE | 444.95 Million USD | 95.686% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 74.381% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1019.837% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -61.252% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -423.687% |
| AVAX Technologies, Inc. | 3.99 Million USD | -380.602% |
| Zenith Capital Corp. | 27.56 Thousand USD | -69521.677% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.552% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -7942.606% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -413.991% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -2719.189% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 83.833% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -112.271% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -28578.151% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1238.623% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 61.814% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -607.837% |
| BioStem Technologies, Inc. | 15.9 Million USD | -20.682% |
| ONE Bio Corp. | 27.49 Million USD | 30.193% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -4030.416% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -69866.828% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1424.31% |
| Agentix Corp. | 2.51 Million USD | -664.532% |
| LadRx Corporation | 2.2 Million USD | -772.245% |
| Cell Source, Inc. | 15.8 Million USD | -21.429% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -42843.44% |
| Regen BioPharma, Inc. | 5.45 Million USD | -251.692% |
| Regen BioPharma, Inc. | 5.45 Million USD | -251.692% |
| NovAccess Global Inc. | 7.86 Million USD | -144.176% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 22.436% |
| Itoco Inc. | 1.65 Million USD | -1061.055% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -835.578% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -217.309% |
| Kadimastem Ltd | 3.5 Million USD | -447.638% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -4453.002% |
| CytoDyn Inc. | 127.89 Million USD | 84.992% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -45819.759% |
| Mobile Lads Corp. | 1.31 Million USD | -1361.29% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1125.376% |
| Qrons Inc. | 1.48 Million USD | -1189.302% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -73.775% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -2273.163% |
| Rebus Holdings, Inc. | 5.24 Million USD | -266.158% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -214.558% |
| International Stem Cell Corporation | 5.27 Million USD | -263.729% |
| Bioxytran, Inc. | 3.24 Million USD | -490.675% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -2967.07% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -315.713% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 53.181% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 13.793% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -847.671% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -250.383% |
| Neutra Corp. | 973.52 Thousand USD | -1871.59% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 33.848% |
| PureTech Health plc | 125.58 Million USD | 84.716% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -410.869% |
| IXICO plc | 1.9 Million USD | -910.055% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 6.503% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 81.423% |
| CSL Limited | 18.62 Billion USD | 99.897% |
| Cellectis S.A. | 249.36 Million USD | 92.303% |